Welcome to Pharmaxis

Pharmaxis is a specialist pharmaceutical company that researches, develops and commercialises new therapies for undertreated respiratory diseases.

Founded on an Australian discovery, Pharmaxis' products are now available worldwide.

Company Highlights

Pharmaxis agrees key CF trial parameters with FDA on Bronchitol

Pharmaxis has concluded a productive end to the review meeting with the United States FDA.

Pharmaxis awarded two ARC linkage grants for fibrotic research

Two of Pharmaxis' research projects conducted in conjunction with the University of Sydney have been awarded funding under the ARC Linkage Projects scheme.

European CF clinical trial in paediatric patients begins

Pharmaxis has enroled the first subject into its European paediatric clinical trial evaluating Bronchitol in cystic fibrosis.

Pharmaxis presents new analyses of pooled cystic fibrosis data at European meeting

Pharmaxis has presented new analyses from the pooled data of its two large scale phase 3 studies in cystic fibrosis.